2020 | 2019 | Name | Country | 2020 | 2019 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| 1 | 1 | Johnson & Johnson | United States | $10,879M | $12,254M | AA+ | AAA- |
| 2 | 2 | Roche | Switzerland | $7,592M | $6,914M | AAA- | AA+ |
| 3 | 3 | Bayer | Germany | $5,149M | $6,209M | AA+ | AAA- |
| 4 | 5 | Abbott | United States | $4,572M | $4,455M | AA | AA |
| 5 | 6 | Merck & Co | United States | $4,296M | $4,141M | AA | AA+ |
| 6 | 4 | Pfizer | United States | $3,814M | $4,776M | AA | AA+ |
| 7 | 9 | Celgene | United States | $3,665M | $3,310M | AA | AA- |
| 8 | 10 | GSK | United Kingdom | $3,519M | $3,286M | AA | AA |
| 9 | 7 | Sanofi | France | $3,475M | $3,384M | AA | AA |
| 10 | AbbVie | United States | $3,420M | $0M | AA | ||
| 11 | 8 | Novartis | Switzerland | 🔒 | 🔒 | 🔒 | 🔒 |
| 12 | AstraZeneca | United Kingdom | 🔒 | 🔒 | 🔒 | 🔒 | |
| 13 | Bristol-Myers Squibb | United States | 🔒 | 🔒 | 🔒 | 🔒 | |
| 14 | Eli Lilly and Company | United States | 🔒 | 🔒 | 🔒 | 🔒 | |
| 15 | Sinopharm | China | 🔒 | 🔒 | 🔒 | 🔒 | |
| 16 | Takeda | Japan | 🔒 | 🔒 | 🔒 | 🔒 | |
| 17 | Amgen | United States | 🔒 | 🔒 | 🔒 | 🔒 | |
| 18 | Novo Nordisk | Denmark | 🔒 | 🔒 | 🔒 | 🔒 | |
| 19 | Gilead Sciences | United States | 🔒 | 🔒 | 🔒 | 🔒 | |
| 20 | Biogen | United States | 🔒 | 🔒 | 🔒 | 🔒 | |
| 21 | Merck KGaA | Germany | 🔒 | 🔒 | 🔒 | 🔒 | |
| 22 | Alcon | United States | 🔒 | 🔒 | 🔒 | 🔒 | |
| 23 | Allergan | United States | 🔒 | 🔒 | 🔒 | 🔒 | |
| 24 | SPH | China | 🔒 | 🔒 | 🔒 | 🔒 | |
| 25 | Teva | Israel | 🔒 | 🔒 | 🔒 | 🔒 |